5-吡啶-3-基吡啶-3-甲醛 | 1214339-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-吡啶-3-基吡啶-3-甲醛
• 英文名称: [3,3']Bipyridinyl-5-carbaldehyde
• 英文别名: [3,3'-Bipyridine]-5-carbaldehyde；5-pyridin-3-ylpyridine-3-carbaldehyde
• CAS: 1214339-67-9
• 化学式: C₁₁H₈N₂O
• 分子量: 184.197
• InChiKey: YVLWSVFFRAXFNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-吡啶-3-基吡啶-3-甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 肼 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 51.0h， 生成 N1-([3,3']-bipyridin-5-ylmethyl)-N1-methylethane-1,2-diamine
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel C₁₂ Vinyl Ketolides

  摘要：

  A novel series Of C-12 vinyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens. The C-12 modification involves replacing the natural C-12 methyl group in the erythromycin core with a vinyl group via chemical synthesis. From the C-12 vinyl macrolide core, a series Of C-12 vinyl ketolides was prepared. Several compounds were found to be potent against macrolide-sensitive and -resistant bacteria. The C-12 vinyl ketolides 6j and 6k showed a similar antimicrobial spectrum and comparable activity to the commercial ketolide telithromycin. However, the pharmacokinetic profiles Of C-12 vinyl ketolides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, larger volumes of distribution, and longer half-lives. These pharmacokinetic differences have a pharmacodynamic effect as both 6j and 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Streptococcus pneumoniae and Haemophilus influenzae.

  DOI：

  10.1021/jm051157a
• 作为产物：
  描述：

  二乙基(3-吡啶基)-硼烷 在 sodium tetrahydroborate 、 四(三苯基膦)钯 、 草酰氯 、 potassium carbonate 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 61.0h， 生成 5-吡啶-3-基吡啶-3-甲醛
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel C₁₂ Vinyl Ketolides

  摘要：

  A novel series Of C-12 vinyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens. The C-12 modification involves replacing the natural C-12 methyl group in the erythromycin core with a vinyl group via chemical synthesis. From the C-12 vinyl macrolide core, a series Of C-12 vinyl ketolides was prepared. Several compounds were found to be potent against macrolide-sensitive and -resistant bacteria. The C-12 vinyl ketolides 6j and 6k showed a similar antimicrobial spectrum and comparable activity to the commercial ketolide telithromycin. However, the pharmacokinetic profiles Of C-12 vinyl ketolides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, larger volumes of distribution, and longer half-lives. These pharmacokinetic differences have a pharmacodynamic effect as both 6j and 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Streptococcus pneumoniae and Haemophilus influenzae.

  DOI：

  10.1021/jm051157a

文献信息

• PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS
  申请人：Université Laval

  公开号：US20150225423A1

  公开（公告）日：2015-08-13

  The present invention features compounds having the Formula (Ia) and (Ib) (e.g., a compound of any of Formulas ((Ia-2)-(Ia-21)), including other tautomers, stereoisomers, E/Z stereoisomers, prodrugs, pharmaceutically acceptable salts, and compositions thereof. The invention also features methods for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient by administering an effective amount of a compound of Formula (Ia) or (Ib). The invention also features a method for treating or preventing pain (e.g., neuropathic pain), inflammation, or epilepsy in a patient that includes administering to a patient in need thereof an effective amount of a compound of Formula (IIa) or (IIb) (e.g., a compound of any of Formulas ((IIa-2)-(IIa-6)). The compounds described herein (e.g., a compound of Formulas (Ia), (Ib), (IIa), or (IIb)) can also be used as anticonvulsants.

  本发明涉及具有式(Ia)和(Ib)的化合物(例如，任何公式((Ia-2)-(Ia-21))的化合物，包括其他互变异构体、立体异构体、E/Z立体异构体、前药、药学上可接受的盐及其组合物。本发明还涉及通过给患者施用式(Ia)或(Ib)的化合物的有效量来治疗或预防疼痛(例如，神经痛)、炎症或癫痫的方法。本发明还涉及一种治疗或预防疼痛(例如，神经痛)、炎症或癫痫的方法，包括向需要的患者施用式(IIa)或(IIb)的化合物的有效量(例如，任何公式((IIa-2)-(IIa-6))的化合物)。本文所描述的化合物(例如，公式(Ia)、(Ib)、(IIa)或(IIb)的化合物)也可用作抗惊厥剂。
• Synthesis, structure, magnetic properties of one‐dimensional Cu‐Ln chains linked by a nitronyl nitroxide radical with two pyridyl groups
  作者：Hongwei Song、Jiao Lu、Xiaotong Wang、Licun Li

  DOI：10.1002/zaac.202300090

  日期：2023.9.14

  CuII ions through its two pyridine groups to produce 1D chain while the aminoxyl moiety of the radical is bound to a Ln (III) ion. Direct-current magnetic susceptibility investigations indicate that ferromagnetic exchanges are dominant and magnetic susceptibility data of Gd derivative are analyzed using a magnetic model, indicating that Cu-NO coupling through pyridine group and Gd-NO direct exchange

  两个新的 Cu−Ln 1D 配位链，其结构式为 [Ln(hfac) 3 Cu(hfac) 2 (NIT-3Py-5-3Py)(H 2 O)] n (Ln III =Gd 1 , Dy 2 ; hfac=六氟乙酰丙酮化物, NIT-3Py-5-3Py=2-(5-(3-吡啶基)-3-吡啶基)-4,4,5,5-四甲基咪唑啉-1-氧基-3-氧化物)通过含有两个吡啶基团的新硝基硝基氧自由基配体。在这两个配合物中，自由基配体结合两个 Cu II离子通过其两个吡啶基团产生一维链，而自由基的氨氧基部分与 Ln (III) 离子结合。直流磁化率研究表明铁磁交换占主导地位，并利用磁模型分析了Gd衍生物的磁化率数据，表明Cu-NO通过吡啶基团偶联和Gd-NO直接交换是铁磁相互作用。Dy 类似物不存在磁弛豫行为。
• METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS
  申请人：Université Laval

  公开号：EP2432776B1

  公开（公告）日：2019-09-11
• METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS
  申请人：Chlorion Pharma, Inc.

  公开号：EP2432776A1

  公开（公告）日：2012-03-28
• US9040538B2
  申请人：——

  公开号：US9040538B2

  公开（公告）日：2015-05-26